Advertisement
Research Article

Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database

  • Erick H. Turner mail,

    turnere@ohsu.edu

    Affiliations: Department of Psychiatry, Oregon Health & Science University, Portland, Oregon, United States of America, Department of Pharmacology, Oregon Health & Science University, Portland, Oregon, United States of America, Center for Ethics in Health Care, Oregon Health & Science University, Portland, Oregon, United States of America, Behavioral Health and Neurosciences Division, Portland Veterans Affairs Medical Center, Portland, Oregon, United States of America

    X
  • Daniel Knoepflmacher,

    Affiliation: School of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Lee Shapley

    Affiliation: School of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Published: March 20, 2012
  • DOI: 10.1371/journal.pmed.1001189

About the Authors

Erick H. Turner
Department of Psychiatry, Oregon Health & Science University, Portland, Oregon, United States of America
Erick H. Turner
Department of Pharmacology, Oregon Health & Science University, Portland, Oregon, United States of America
Erick H. Turner
Center for Ethics in Health Care, Oregon Health & Science University, Portland, Oregon, United States of America
Erick H. Turner
Behavioral Health and Neurosciences Division, Portland Veterans Affairs Medical Center, Portland, Oregon, United States of America
Daniel Knoepflmacher, Lee Shapley
School of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America

Corresponding Author

Email: turnere@ohsu.edu

Competing Interests

From 1998 to 2001, ET served as a medical reviewer at the US Food and Drug Administration (FDA). Subsequently, but ending in 2005, ET provided outside consulting to Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. From 2004 to 2005, ET was on the speaker's bureaus of Eli Lilly, AstraZeneca, and Bristol-Myers Squibb. LS is Scorecard Director for the AMSA Pharmfree Scorecard, and a fourth year medical student at Oregon Health & Science University (OHSU). DK is also a fourth year medical student at OHSU and has no competing interests to report.

Author Contributions

Conceived and designed the experiments: ET. Performed the experiments: ET DK LS. Analyzed the data: ET. Contributed reagents/materials/analysis tools: ET. Wrote the first draft: ET. Wrote the paper: ET DK LS. ICMJE criteria for authorship read and met: ET DK LS. Agree with the manuscript's results and conclusions: ET DK LS.